Trial · NCT03696121
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of eligible patients who received allocated treatment | 90 days | Number - higher number indicates feasibility of trial |
| Primary | Rate of eligible patients randomised | 18 months | Shorter period of time to recruit number of patients indicates trial is feasibility;e |
| Primary | Proportion of eligible patients and randomised | 18 months | Are there sufficient numbers of patients to justify a larger trial |
| Primary | Proportion of participants followed up at 90 days | 90 days | Higher number indicates feasibility |
| Primary | Proportion of patients with full outcome data available, and reasons for non-availability | 90 days | Higher number indicates feasibility |
| Primary | Proportion of eligible patients approached | 18 months | Higher number indicates feasibility |
| Primary | Adherence to intervention | 18 months | Higher number indicates feasibility |
| Secondary | Death or dependency at 90 days | 18 months | Lower number indicates positive outcome |
| Secondary | Number of patients dead or suffered serious adverse events | Day 28 and 90 | Number - higher number indicates worse outcome |
| Secondary | Change in intracerebral haemorrhage volume at 24 hours | 24 hours | Higher volume indicates worse outcome |
| Secondary | Disability - Barthel index | Day 90 | Scores range from 0 - 100, with lower scores indicating increased disability. |
| Secondary | Quality of life - EuroQol | Day 90 | Consists of two parts: a descriptive system (Part I) and a visual analogue scale (VAS) (Part II). Part 1 consists of 5 single-item dimensions. Scores range from 5 - 15 with lower scores indicating no problems to higher scores indicating extreme problems. Part II uses a vertical graduated VAS (thermometer) to measure health status, ranging from worst imaginable health state (0) to best imaginable health state (100). |
| Secondary | Cognition - telephone MMSE | Day 90 | Scores are out of 22, with lower scores indicating cognitive impairment |
| Secondary | Length of hospital stay | Day 90 | Number of days - higher number indicates longer length of stay |
| Secondary | Discharge destination | 18 months | Destination of participant following discharge from hospital |
| Secondary | Health Economic assessment (EQ5D) | 90 Days | Range 0-100, Higher score indicates better health |
| Secondary | Serious adverse events (including thromboembolic events) | Day 90 | Higher volume indicates worse outcome |
| Secondary | Change in factor vIII, Von Willebrand Factor antigen and Von Willebrand Factor activity will be assessed | One hour post administration of Desmopressin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03696121/registered